NeoGenomics, Inc. (NASDAQ:NEO) – Research analysts at SVB Leerink decreased their Q4 2020 EPS estimates for shares of NeoGenomics in a research note issued on Thursday, January 7th. SVB Leerink analyst P. Souda now expects that the medical research company will post earnings per share of $0.03 for the quarter, down from their previous forecast of $0.04. SVB Leerink currently has a “Outperform” rating and a $60.00 target price on the stock. SVB Leerink also issued estimates for NeoGenomics’ Q3 2021 earnings at $0.06 EPS, FY2021 earnings at $0.24 EPS, Q1 2022 earnings at $0.09 EPS, Q2 2022 earnings at $0.10 EPS, Q3 2022 earnings at $0.12 EPS and Q4 2022 earnings at $0.14 EPS.
Other equities analysts also recently issued reports about the stock. Needham & Company LLC lifted their price target on shares of NeoGenomics from $39.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. BidaskClub downgraded shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Monday, December 28th. Benchmark raised their price objective on shares of NeoGenomics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Raymond James raised their price objective on shares of NeoGenomics from $40.00 to $48.00 and gave the company an “outperform” rating in a research report on Wednesday, October 28th. Finally, BTIG Research initiated coverage on shares of NeoGenomics in a research report on Friday, December 11th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. NeoGenomics presently has a consensus rating of “Buy” and a consensus price target of $41.79.
Shares of NEO stock opened at $52.44 on Monday. NeoGenomics has a 12-month low of $20.47 and a 12-month high of $57.07. The company has a market capitalization of $5.82 billion, a P/E ratio of -1,747.42 and a beta of 0.78. The firm has a 50-day moving average price of $50.69 and a 200 day moving average price of $40.99. The company has a quick ratio of 6.22, a current ratio of 6.54 and a debt-to-equity ratio of 0.25.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 27th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The firm had revenue of $125.40 million during the quarter, compared to the consensus estimate of $126.23 million. During the same period last year, the firm posted $0.07 EPS. The firm’s quarterly revenue was up 19.8% on a year-over-year basis.
The firm also recently declared a dividend, which was paid on Wednesday, December 30th. Stockholders of record on Friday, December 18th were given a dividend of $0.40 per share. This represents a dividend yield of 3.13%. The ex-dividend date of this dividend was Thursday, December 17th.
In other news, CEO Oort Douglas M. Van sold 340,000 shares of NeoGenomics stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $42.01, for a total transaction of $14,283,400.00. Following the completion of the sale, the chief executive officer now owns 2,384,038 shares in the company, valued at approximately $100,153,436.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider George Cardoza sold 52,926 shares of NeoGenomics stock in a transaction that occurred on Tuesday, November 24th. The stock was sold at an average price of $45.19, for a total transaction of $2,391,725.94. Following the sale, the insider now owns 423,828 shares of the company’s stock, valued at approximately $19,152,787.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 754,561 shares of company stock valued at $33,557,193. 6.50% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC increased its holdings in NeoGenomics by 150.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 1,000 shares of the medical research company’s stock worth $37,000 after acquiring an additional 600 shares during the last quarter. Fiduciary Planning LLC purchased a new position in shares of NeoGenomics during the third quarter valued at approximately $41,000. FinTrust Capital Advisors LLC increased its stake in shares of NeoGenomics by 27.0% during the third quarter. FinTrust Capital Advisors LLC now owns 1,270 shares of the medical research company’s stock valued at $47,000 after buying an additional 270 shares during the period. Flagship Harbor Advisors LLC increased its stake in shares of NeoGenomics by 48.0% during the third quarter. Flagship Harbor Advisors LLC now owns 1,310 shares of the medical research company’s stock valued at $48,000 after buying an additional 425 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of NeoGenomics during the third quarter valued at approximately $55,000. 86.09% of the stock is currently owned by institutional investors and hedge funds.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Further Reading: 52 Week Highs
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.